Spyre TherapeuticsFRA:3920 +0.65%33 Market Cap is €6,606.13 Mil as of Jul. 03, 2026. GuruFocus rates FRA:3920 with a GF Score™ of 33/100. The stock has 4 warning signs investors should review. Among 1,426 Biotechnology companies, Spyre Therapeutics ranks better than 95.93% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Spyre Therapeutics's share price for the quarter that ended in Mar. 2026 was €39.6. Spyre Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 78.84 Mil. Therefore, Spyre Therapeutics's market cap for the quarter that ended in Mar. 2026 was €3,122.06 Mil.
Spyre Therapeutics's quarterly market cap
increased
from Sep. 2025 (€834.51 Mil) to Dec. 2025 (€2,142.41 Mil) and
increased
from Dec. 2025 (€2,142.41 Mil) to Mar. 2026 (€3,122.06 Mil).
Spyre Therapeutics's annual market cap
increased
from Dec. 2023 (€0.00 Mil) to Dec. 2024 (€1,349.76 Mil) and
increased
from Dec. 2024 (€1,349.76 Mil) to Dec. 2025 (€2,142.41 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Spyre Therapeutics's Enterprise Value for Today is €6,091.86 Mil.
Spyre Therapeutics (FRA:3920) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Spyre Therapeutics Market Cap Related Terms
Spyre Therapeutics Market Cap Historical Data
* Premium members only.
The historical data trend for Spyre Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:3920 vs MIRM, RYTM, PTGX: Market Cap Comparison
For the Biotechnology subindustry, Spyre Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spyre Therapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Spyre Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Spyre Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Spyre Therapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spyre Therapeutics (FRA:3920) has a Market Cap of €6,606.13 Mil as of Jul. 03, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Spyre Therapeutics and its competitors. According to the industry distribution chart, Spyre Therapeutics ranks #58 out of 1426 companies in the Biotechnology industry, placing it in the top 4.1%.
Is Spyre Therapeutics' Market Cap too high?
Spyre Therapeutics' current Market Cap is €6,606.13 Mil. Based on the distribution chart, Spyre Therapeutics ranks #58 out of 1426 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Spyre Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Spyre Therapeutics' Market Cap compare to MIRM and RYTM?
According to the Biotechnology industry distribution chart, Spyre Therapeutics ranks #58 out of 1426 companies for Market Cap. This places Spyre Therapeutics in the top 4% of its industry — outperforming the majority of peers. The industry median Market Cap is 119.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.23, based on 1,426 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Spyre Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 119.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Spyre Therapeutics's current Market Cap is €6,606.13 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spyre Therapeutics stock overvalued right now?
Spyre Therapeutics (FRA:3920) has a current Market Cap of €6,606.13 Mil. The current Market Cap is €6,606.13 Mil. Spyre Therapeutics' overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Spyre Therapeutics (FRA:3920), the current Market Cap is €6,606.13 Mil as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting ?4?7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
33GF Score
Get the complete analysis for FRA:3920
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:3920 has been successfully added to your 
